{"id":9482,"date":"2020-03-27T10:15:10","date_gmt":"2020-03-27T17:15:10","guid":{"rendered":"https:\/\/drugpolicy.ca\/?p=9482"},"modified":"2021-11-05T16:13:26","modified_gmt":"2021-11-05T23:13:26","slug":"covid-19-information-for-opioid-agonist-treatment-prescribers-and-pharmacists","status":"publish","type":"post","link":"https:\/\/new.drugpolicy.ca\/fr\/covid-19-information-for-opioid-agonist-treatment-prescribers-and-pharmacists\/","title":{"rendered":"COVID-19: Information for OAT Prescribers and Pharmacists"},"content":{"rendered":"\n<iframe loading=\"lazy\" class=\"scribd_iframe_embed\" title=\"COVID-19 Bulletin (1)\" src=\"https:\/\/www.scribd.com\/embeds\/453570439\/content?start_page=1&amp;view_mode=scroll&amp;access_key=key-7DQ2IfbJVqE5Yg9xrYbQ\" data-auto-height=\"false\" data-aspect-ratio=\"0.7729220222793488\" scrolling=\"no\" id=\"doc_24819\" width=\"100%\" height=\"600\" frameborder=\"0\"><\/iframe>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-background is-style-dots\" style=\"background-color:#ffffff;color:#ffffff\"\/>\n\n\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link has-background\" href=\"https:\/\/drugpolicy.ca\/wp-content\/uploads\/2020\/03\/COVID-19-Bulletin-1.pdf\" style=\"background-color:#c31424\" target=\"_blank\" rel=\"noreferrer noopener\">Download PDF<\/a><\/div>\n<\/div>\n\n\n\n<p><p style=\"margin-top:30px; text-align:center\"><strong>Click <a href=\"https:\/\/drugpolicy.ca\/covid-19-harm-reduction-resources\/\" target=\"_blank\" rel=\"noreferrer noopener\" aria-label=\"HERE (opens in a new tab)\">HERE<\/a> for more resources<\/strong><\/p><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">On March 11, 2020, the World Health Organization declared the novel coronavirus, COVID-19, a pandemic, citing concern over alarming levels of spread and severity across the globe. The novel coronavirus has caused a global outbreak of respiratory infections since its discovery in December 2019. For most, this coronavirus causes only mild to moderate symptoms including fever and cough, however, older adults and those with existing health problems are at greater risk for more severe symptoms such as pneumonia.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The situation regarding COVID-19 continues to evolve here in BC, Canada, and other jurisdictions in the world. Federal and provincial health officials have urged individuals on chronic medications to acquire an adequate supply of prescription drugs. Ensuring uninterrupted access to essential medications, including opioid agonist treatment (OAT) medications for patients with opioid use disorder, is of critical importance to reduce the risk of harms and death that can be associated with medication destabilization.<\/p>\n\n\n\n<div class=\"widget signup-widget mb-5\">\r\n<p class=\"lead\"><strong>\u00cates-vous pr\u00eat(e) \u00e0 aider ?<\/strong><\/p>\r\n<p>Soutenez des politiques sur les drogues bas\u00e9es sur la justice sociale, la compassion et les preuves. Inscrivez-vous \u00e0 notre newsletter pour obtenir des mises \u00e0 jour et d\u00e9couvrez comment vous pouvez agir avec nous.<\/p>\r\n<!-- form.123formbuilder.com script begins here --><script type=\"text\/javascript\" defer=\"defer\" src=\"https:\/\/form.123formbuilder.com\/embed\/6415583.js\" data-role=\"form\" data-default-width=\"650px\"><\/script><!-- form.123formbuilder.com script ends here -->\r\n<\/div>\r\n\n\n\n<ul class=\"wp-block-social-links aligncenter is-style-default is-layout-flex wp-block-social-links-is-layout-flex\"><li class=\"wp-social-link wp-social-link-twitter  wp-block-social-link\"><a rel=\"noopener nofollow\" target=\"_blank\" href=\"https:\/\/www.twitter.com\/candrugpolicy\" class=\"wp-block-social-link-anchor\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" version=\"1.1\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" aria-hidden=\"true\" focusable=\"false\"><path d=\"M22.23,5.924c-0.736,0.326-1.527,0.547-2.357,0.646c0.847-0.508,1.498-1.312,1.804-2.27 c-0.793,0.47-1.671,0.812-2.606,0.996C18.324,4.498,17.257,4,16.077,4c-2.266,0-4.103,1.837-4.103,4.103 c0,0.322,0.036,0.635,0.106,0.935C8.67,8.867,5.647,7.234,3.623,4.751C3.27,5.357,3.067,6.062,3.067,6.814 c0,1.424,0.724,2.679,1.825,3.415c-0.673-0.021-1.305-0.206-1.859-0.513c0,0.017,0,0.034,0,0.052c0,1.988,1.414,3.647,3.292,4.023 c-0.344,0.094-0.707,0.144-1.081,0.144c-0.264,0-0.521-0.026-0.772-0.074c0.522,1.63,2.038,2.816,3.833,2.85 c-1.404,1.1-3.174,1.756-5.096,1.756c-0.331,0-0.658-0.019-0.979-0.057c1.816,1.164,3.973,1.843,6.29,1.843 c7.547,0,11.675-6.252,11.675-11.675c0-0.178-0.004-0.355-0.012-0.531C20.985,7.47,21.68,6.747,22.23,5.924z\"><\/path><\/svg><span class=\"wp-block-social-link-label screen-reader-text\">Twitter<\/span><\/a><\/li>\n\n<li class=\"wp-social-link wp-social-link-facebook  wp-block-social-link\"><a rel=\"noopener nofollow\" target=\"_blank\" href=\"https:\/\/www.facebook.com\/candrugpolicy\" class=\"wp-block-social-link-anchor\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" version=\"1.1\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" aria-hidden=\"true\" focusable=\"false\"><path d=\"M12 2C6.5 2 2 6.5 2 12c0 5 3.7 9.1 8.4 9.9v-7H7.9V12h2.5V9.8c0-2.5 1.5-3.9 3.8-3.9 1.1 0 2.2.2 2.2.2v2.5h-1.3c-1.2 0-1.6.8-1.6 1.6V12h2.8l-.4 2.9h-2.3v7C18.3 21.1 22 17 22 12c0-5.5-4.5-10-10-10z\"><\/path><\/svg><span class=\"wp-block-social-link-label screen-reader-text\">Facebook<\/span><\/a><\/li>\n\n<li class=\"wp-social-link wp-social-link-instagram  wp-block-social-link\"><a rel=\"noopener nofollow\" target=\"_blank\" href=\"https:\/\/www.instagram.com\/candrugpolicy\" class=\"wp-block-social-link-anchor\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" version=\"1.1\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" aria-hidden=\"true\" focusable=\"false\"><path d=\"M12,4.622c2.403,0,2.688,0.009,3.637,0.052c0.877,0.04,1.354,0.187,1.671,0.31c0.42,0.163,0.72,0.358,1.035,0.673 c0.315,0.315,0.51,0.615,0.673,1.035c0.123,0.317,0.27,0.794,0.31,1.671c0.043,0.949,0.052,1.234,0.052,3.637 s-0.009,2.688-0.052,3.637c-0.04,0.877-0.187,1.354-0.31,1.671c-0.163,0.42-0.358,0.72-0.673,1.035 c-0.315,0.315-0.615,0.51-1.035,0.673c-0.317,0.123-0.794,0.27-1.671,0.31c-0.949,0.043-1.233,0.052-3.637,0.052 s-2.688-0.009-3.637-0.052c-0.877-0.04-1.354-0.187-1.671-0.31c-0.42-0.163-0.72-0.358-1.035-0.673 c-0.315-0.315-0.51-0.615-0.673-1.035c-0.123-0.317-0.27-0.794-0.31-1.671C4.631,14.688,4.622,14.403,4.622,12 s0.009-2.688,0.052-3.637c0.04-0.877,0.187-1.354,0.31-1.671c0.163-0.42,0.358-0.72,0.673-1.035 c0.315-0.315,0.615-0.51,1.035-0.673c0.317-0.123,0.794-0.27,1.671-0.31C9.312,4.631,9.597,4.622,12,4.622 M12,3 C9.556,3,9.249,3.01,8.289,3.054C7.331,3.098,6.677,3.25,6.105,3.472C5.513,3.702,5.011,4.01,4.511,4.511 c-0.5,0.5-0.808,1.002-1.038,1.594C3.25,6.677,3.098,7.331,3.054,8.289C3.01,9.249,3,9.556,3,12c0,2.444,0.01,2.751,0.054,3.711 c0.044,0.958,0.196,1.612,0.418,2.185c0.23,0.592,0.538,1.094,1.038,1.594c0.5,0.5,1.002,0.808,1.594,1.038 c0.572,0.222,1.227,0.375,2.185,0.418C9.249,20.99,9.556,21,12,21s2.751-0.01,3.711-0.054c0.958-0.044,1.612-0.196,2.185-0.418 c0.592-0.23,1.094-0.538,1.594-1.038c0.5-0.5,0.808-1.002,1.038-1.594c0.222-0.572,0.375-1.227,0.418-2.185 C20.99,14.751,21,14.444,21,12s-0.01-2.751-0.054-3.711c-0.044-0.958-0.196-1.612-0.418-2.185c-0.23-0.592-0.538-1.094-1.038-1.594 c-0.5-0.5-1.002-0.808-1.594-1.038c-0.572-0.222-1.227-0.375-2.185-0.418C14.751,3.01,14.444,3,12,3L12,3z M12,7.378 c-2.552,0-4.622,2.069-4.622,4.622S9.448,16.622,12,16.622s4.622-2.069,4.622-4.622S14.552,7.378,12,7.378z M12,15 c-1.657,0-3-1.343-3-3s1.343-3,3-3s3,1.343,3,3S13.657,15,12,15z M16.804,6.116c-0.596,0-1.08,0.484-1.08,1.08 s0.484,1.08,1.08,1.08c0.596,0,1.08-0.484,1.08-1.08S17.401,6.116,16.804,6.116z\"><\/path><\/svg><span class=\"wp-block-social-link-label screen-reader-text\">Instagram<\/span><\/a><\/li><\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Many patients on OAT currently receive daily witnessed medications. In the context of the COVID-19 pandemic, there may be additional considerations for access that prescribers and pharmacists should be aware of.<\/p>\n","protected":false},"author":38,"featured_media":9484,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_crdt_document":"","footnotes":""},"categories":[1119],"tags":[1124],"class_list":["post-9482","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-covid","tag-safe-supply-oat-and-ioat"],"acf":[],"mb":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>COVID-19: Information for OAT Prescribers and Pharmacists - Canadian Drug Policy Coalition<\/title>\n<meta name=\"description\" content=\"Many patients on OAT currently receive daily witnessed medications. In the context of the COVID-19 pandemic, there may be additional considerations for access that prescribers and pharmacists should be aware of.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/new.drugpolicy.ca\/fr\/covid-19-information-for-opioid-agonist-treatment-prescribers-and-pharmacists\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"COVID-19: Information for OAT Prescribers and Pharmacists - Canadian Drug Policy Coalition\" \/>\n<meta property=\"og:description\" content=\"Many patients on OAT currently receive daily witnessed medications. In the context of the COVID-19 pandemic, there may be additional considerations for access that prescribers and pharmacists should be aware of.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/new.drugpolicy.ca\/fr\/covid-19-information-for-opioid-agonist-treatment-prescribers-and-pharmacists\/\" \/>\n<meta property=\"og:site_name\" content=\"Canadian Drug Policy Coalition\" \/>\n<meta property=\"article:published_time\" content=\"2020-03-27T17:15:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-11-05T23:13:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2020\/03\/Screen-Shot-2020-03-27-at-11.07.21-AM-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"902\" \/>\n\t<meta property=\"og:image:height\" content=\"535\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Canadian Drug Policy Coalition\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Canadian Drug Policy Coalition\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/covid-19-information-for-opioid-agonist-treatment-prescribers-and-pharmacists\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/covid-19-information-for-opioid-agonist-treatment-prescribers-and-pharmacists\\\/\"},\"author\":{\"name\":\"Canadian Drug Policy Coalition\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#\\\/schema\\\/person\\\/c32110f234bdb1f5d978710b6b406a30\"},\"headline\":\"COVID-19: Information for OAT Prescribers and Pharmacists\",\"datePublished\":\"2020-03-27T17:15:10+00:00\",\"dateModified\":\"2021-11-05T23:13:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/covid-19-information-for-opioid-agonist-treatment-prescribers-and-pharmacists\\\/\"},\"wordCount\":162,\"publisher\":{\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/covid-19-information-for-opioid-agonist-treatment-prescribers-and-pharmacists\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/new.drugpolicy.ca\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/Screen-Shot-2020-03-27-at-11.07.21-AM-1.png\",\"keywords\":[\"safe supply OAT and iOAT\"],\"articleSection\":[\"covid\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/covid-19-information-for-opioid-agonist-treatment-prescribers-and-pharmacists\\\/\",\"url\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/covid-19-information-for-opioid-agonist-treatment-prescribers-and-pharmacists\\\/\",\"name\":\"COVID-19: Information for OAT Prescribers and Pharmacists - Canadian Drug Policy Coalition\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/covid-19-information-for-opioid-agonist-treatment-prescribers-and-pharmacists\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/covid-19-information-for-opioid-agonist-treatment-prescribers-and-pharmacists\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/new.drugpolicy.ca\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/Screen-Shot-2020-03-27-at-11.07.21-AM-1.png\",\"datePublished\":\"2020-03-27T17:15:10+00:00\",\"dateModified\":\"2021-11-05T23:13:26+00:00\",\"description\":\"Many patients on OAT currently receive daily witnessed medications. In the context of the COVID-19 pandemic, there may be additional considerations for access that prescribers and pharmacists should be aware of.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/covid-19-information-for-opioid-agonist-treatment-prescribers-and-pharmacists\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/covid-19-information-for-opioid-agonist-treatment-prescribers-and-pharmacists\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/covid-19-information-for-opioid-agonist-treatment-prescribers-and-pharmacists\\\/#primaryimage\",\"url\":\"https:\\\/\\\/new.drugpolicy.ca\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/Screen-Shot-2020-03-27-at-11.07.21-AM-1.png\",\"contentUrl\":\"https:\\\/\\\/new.drugpolicy.ca\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/Screen-Shot-2020-03-27-at-11.07.21-AM-1.png\",\"width\":902,\"height\":535,\"caption\":\"BC Centre on Substance use logo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/covid-19-information-for-opioid-agonist-treatment-prescribers-and-pharmacists\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"COVID-19: Information for OAT Prescribers and Pharmacists\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/\",\"name\":\"Canadian Drug Policy Coalition\",\"description\":\"Change policy. Save lives.\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#organization\",\"name\":\"Canadian Drug Policy Coalition\",\"url\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/drugpolicy.ca\\\/wp-content\\\/uploads\\\/2019\\\/04\\\/CDPC-logo-white-on-red-150-dpi.jpg\",\"contentUrl\":\"https:\\\/\\\/drugpolicy.ca\\\/wp-content\\\/uploads\\\/2019\\\/04\\\/CDPC-logo-white-on-red-150-dpi.jpg\",\"width\":332,\"height\":333,\"caption\":\"Canadian Drug Policy Coalition\"},\"image\":{\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#\\\/schema\\\/person\\\/c32110f234bdb1f5d978710b6b406a30\",\"name\":\"Canadian Drug Policy Coalition\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9f79e2b1a0ccc3ac68e2c3b14806186aa5e053de86cb3e0ee34e1971e8c4a3f7?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9f79e2b1a0ccc3ac68e2c3b14806186aa5e053de86cb3e0ee34e1971e8c4a3f7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9f79e2b1a0ccc3ac68e2c3b14806186aa5e053de86cb3e0ee34e1971e8c4a3f7?s=96&d=mm&r=g\",\"caption\":\"Canadian Drug Policy Coalition\"},\"description\":\"Advocating for public health- and human rights-based drug policy grounded in evidence, compassion, and social justice\",\"url\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/author\\\/canadian-drug-policy-coalition\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"COVID-19: Information for OAT Prescribers and Pharmacists - Canadian Drug Policy Coalition","description":"Many patients on OAT currently receive daily witnessed medications. In the context of the COVID-19 pandemic, there may be additional considerations for access that prescribers and pharmacists should be aware of.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/new.drugpolicy.ca\/fr\/covid-19-information-for-opioid-agonist-treatment-prescribers-and-pharmacists\/","og_locale":"fr_FR","og_type":"article","og_title":"COVID-19: Information for OAT Prescribers and Pharmacists - Canadian Drug Policy Coalition","og_description":"Many patients on OAT currently receive daily witnessed medications. In the context of the COVID-19 pandemic, there may be additional considerations for access that prescribers and pharmacists should be aware of.","og_url":"https:\/\/new.drugpolicy.ca\/fr\/covid-19-information-for-opioid-agonist-treatment-prescribers-and-pharmacists\/","og_site_name":"Canadian Drug Policy Coalition","article_published_time":"2020-03-27T17:15:10+00:00","article_modified_time":"2021-11-05T23:13:26+00:00","og_image":[{"width":902,"height":535,"url":"https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2020\/03\/Screen-Shot-2020-03-27-at-11.07.21-AM-1.png","type":"image\/png"}],"author":"Canadian Drug Policy Coalition","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Canadian Drug Policy Coalition","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/new.drugpolicy.ca\/fr\/covid-19-information-for-opioid-agonist-treatment-prescribers-and-pharmacists\/#article","isPartOf":{"@id":"https:\/\/new.drugpolicy.ca\/fr\/covid-19-information-for-opioid-agonist-treatment-prescribers-and-pharmacists\/"},"author":{"name":"Canadian Drug Policy Coalition","@id":"https:\/\/www.drugpolicy.ca\/fr\/#\/schema\/person\/c32110f234bdb1f5d978710b6b406a30"},"headline":"COVID-19: Information for OAT Prescribers and Pharmacists","datePublished":"2020-03-27T17:15:10+00:00","dateModified":"2021-11-05T23:13:26+00:00","mainEntityOfPage":{"@id":"https:\/\/new.drugpolicy.ca\/fr\/covid-19-information-for-opioid-agonist-treatment-prescribers-and-pharmacists\/"},"wordCount":162,"publisher":{"@id":"https:\/\/www.drugpolicy.ca\/fr\/#organization"},"image":{"@id":"https:\/\/new.drugpolicy.ca\/fr\/covid-19-information-for-opioid-agonist-treatment-prescribers-and-pharmacists\/#primaryimage"},"thumbnailUrl":"https:\/\/new.drugpolicy.ca\/wp-content\/uploads\/2020\/03\/Screen-Shot-2020-03-27-at-11.07.21-AM-1.png","keywords":["safe supply OAT and iOAT"],"articleSection":["covid"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/new.drugpolicy.ca\/fr\/covid-19-information-for-opioid-agonist-treatment-prescribers-and-pharmacists\/","url":"https:\/\/new.drugpolicy.ca\/fr\/covid-19-information-for-opioid-agonist-treatment-prescribers-and-pharmacists\/","name":"COVID-19: Information for OAT Prescribers and Pharmacists - Canadian Drug Policy Coalition","isPartOf":{"@id":"https:\/\/www.drugpolicy.ca\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/new.drugpolicy.ca\/fr\/covid-19-information-for-opioid-agonist-treatment-prescribers-and-pharmacists\/#primaryimage"},"image":{"@id":"https:\/\/new.drugpolicy.ca\/fr\/covid-19-information-for-opioid-agonist-treatment-prescribers-and-pharmacists\/#primaryimage"},"thumbnailUrl":"https:\/\/new.drugpolicy.ca\/wp-content\/uploads\/2020\/03\/Screen-Shot-2020-03-27-at-11.07.21-AM-1.png","datePublished":"2020-03-27T17:15:10+00:00","dateModified":"2021-11-05T23:13:26+00:00","description":"Many patients on OAT currently receive daily witnessed medications. In the context of the COVID-19 pandemic, there may be additional considerations for access that prescribers and pharmacists should be aware of.","breadcrumb":{"@id":"https:\/\/new.drugpolicy.ca\/fr\/covid-19-information-for-opioid-agonist-treatment-prescribers-and-pharmacists\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/new.drugpolicy.ca\/fr\/covid-19-information-for-opioid-agonist-treatment-prescribers-and-pharmacists\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/new.drugpolicy.ca\/fr\/covid-19-information-for-opioid-agonist-treatment-prescribers-and-pharmacists\/#primaryimage","url":"https:\/\/new.drugpolicy.ca\/wp-content\/uploads\/2020\/03\/Screen-Shot-2020-03-27-at-11.07.21-AM-1.png","contentUrl":"https:\/\/new.drugpolicy.ca\/wp-content\/uploads\/2020\/03\/Screen-Shot-2020-03-27-at-11.07.21-AM-1.png","width":902,"height":535,"caption":"BC Centre on Substance use logo"},{"@type":"BreadcrumbList","@id":"https:\/\/new.drugpolicy.ca\/fr\/covid-19-information-for-opioid-agonist-treatment-prescribers-and-pharmacists\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.drugpolicy.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"COVID-19: Information for OAT Prescribers and Pharmacists"}]},{"@type":"WebSite","@id":"https:\/\/www.drugpolicy.ca\/fr\/#website","url":"https:\/\/www.drugpolicy.ca\/fr\/","name":"Canadian Drug Policy Coalition","description":"Change policy. Save lives.","publisher":{"@id":"https:\/\/www.drugpolicy.ca\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.drugpolicy.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.drugpolicy.ca\/fr\/#organization","name":"Canadian Drug Policy Coalition","url":"https:\/\/www.drugpolicy.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.drugpolicy.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/drugpolicy.ca\/wp-content\/uploads\/2019\/04\/CDPC-logo-white-on-red-150-dpi.jpg","contentUrl":"https:\/\/drugpolicy.ca\/wp-content\/uploads\/2019\/04\/CDPC-logo-white-on-red-150-dpi.jpg","width":332,"height":333,"caption":"Canadian Drug Policy Coalition"},"image":{"@id":"https:\/\/www.drugpolicy.ca\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.drugpolicy.ca\/fr\/#\/schema\/person\/c32110f234bdb1f5d978710b6b406a30","name":"Canadian Drug Policy Coalition","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/9f79e2b1a0ccc3ac68e2c3b14806186aa5e053de86cb3e0ee34e1971e8c4a3f7?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9f79e2b1a0ccc3ac68e2c3b14806186aa5e053de86cb3e0ee34e1971e8c4a3f7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9f79e2b1a0ccc3ac68e2c3b14806186aa5e053de86cb3e0ee34e1971e8c4a3f7?s=96&d=mm&r=g","caption":"Canadian Drug Policy Coalition"},"description":"Advocating for public health- and human rights-based drug policy grounded in evidence, compassion, and social justice","url":"https:\/\/new.drugpolicy.ca\/fr\/author\/canadian-drug-policy-coalition\/"}]}},"mfb_rest_fields":["title","yoast_head","yoast_head_json"],"_links":{"self":[{"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/posts\/9482","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/comments?post=9482"}],"version-history":[{"count":6,"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/posts\/9482\/revisions"}],"predecessor-version":[{"id":16912,"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/posts\/9482\/revisions\/16912"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/media\/9484"}],"wp:attachment":[{"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/media?parent=9482"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/categories?post=9482"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/tags?post=9482"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}